Literature DB >> 21138871

DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer.

Brian M Alexander1, Kam Sprott, D Allan Farrow, XiaoZhe Wang, Alan D D'Andrea, Stuart J Schnitt, Laura C Collins, David T Weaver, Judy E Garber.   

Abstract

PURPOSE: To evaluate the prognostic utility of immunohistochemical assessment of key proteins in multiple DNA repair pathways in triple-negative breast cancer (TNBC; estrogen receptor negative, progesterone receptor negative, and HER2/neu negative by immunohistochemistry). EXPERIMENTAL
DESIGN: Archived clinically annotated tumor specimens from 112 women with TNBC were immunostained with antibodies against DNA repair proteins and scored using digital image analysis. The cohort was divided into training and test sets for development of a multiantibody model. Scores were combined with clinical data to assess association with outcome.
RESULTS: Low XPF (P = 0.005), pMK2 (P = 0.01), MLH; P = 0.002), and FANCD2 (P = 0.001) were each associated with shorter time to recurrence (TTR) in univariate analysis. A 4-antibody model could segregate high-risk and low-risk groups on the basis of TTR in both the training (relative risk [RR] = 3.52; P = 9.05E-07) and test (RR 2.67; P = 0.019) cohorts.
CONCLUSIONS: DNA repair proteins may be useful as prognostic markers in TNBC. Further study in larger, uniformly treated cohorts with additional clinical parameters is warranted. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138871      PMCID: PMC4220607          DOI: 10.1158/1078-0432.CCR-10-0292

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  A phylogenomic study of DNA repair genes, proteins, and processes.

Authors:  J A Eisen; P C Hanawalt
Journal:  Mutat Res       Date:  1999-12-07       Impact factor: 2.433

2.  Positional cloning of a novel Fanconi anemia gene, FANCD2.

Authors:  C Timmers; T Taniguchi; J Hejna; C Reifsteck; L Lucas; D Bruun; M Thayer; B Cox; S Olson; A D D'Andrea; R Moses; M Grompe
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 3.  Genome maintenance mechanisms for preventing cancer.

Authors:  J H Hoeijmakers
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells.

Authors:  I U De Silva; P J McHugh; P H Clingen; J A Hartley
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

Authors:  I Garcia-Higuera; T Taniguchi; S Ganesan; M S Meyn; C Timmers; J Hejna; M Grompe; A D D'Andrea
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

6.  Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.

Authors:  Wataru Sakai; Elizabeth M Swisher; Céline Jacquemont; Kurapaty Venkatapoorna Chandramohan; Fergus J Couch; Simon P Langdon; Kaitlyn Wurz; Jake Higgins; Emily Villegas; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 7.  How the fanconi anemia pathway guards the genome.

Authors:  George-Lucian Moldovan; Alan D D'Andrea
Journal:  Annu Rev Genet       Date:  2009       Impact factor: 16.830

8.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.

Authors:  T Byrski; T Huzarski; R Dent; J Gronwald; D Zuziak; C Cybulski; J Kladny; B Gorski; J Lubinski; S A Narod
Journal:  Breast Cancer Res Treat       Date:  2008-07-23       Impact factor: 4.872

9.  XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair.

Authors:  Nikhil Bhagwat; Anna L Olsen; Anderson T Wang; Katsuhiro Hanada; Patricia Stuckert; Roland Kanaar; Alan D'Andrea; Laura J Niedernhofer; Peter J McHugh
Journal:  Mol Cell Biol       Date:  2009-10-05       Impact factor: 4.272

10.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Authors:  Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

View more
  10 in total

1.  The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Authors:  M Javle; N J Curtin
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.

Authors:  Zheng-mao Lu; Tian-hang Luo; Ming-ming Nie; Guo-en Fang; Li-ye Ma; Xu-chao Xue; Guo Wei; Chong-we Ke; Jian-wei Bi
Journal:  Tumour Biol       Date:  2013-12-08

3.  Triple negative breast cancers have a reduced expression of DNA repair genes.

Authors:  Enilze Ribeiro; Monica Ganzinelli; Daniele Andreis; Ramona Bertoni; Roberto Giardini; Stephen B Fox; Massimo Broggini; Alberto Bottini; Vanessa Zanoni; Letizia Bazzola; Chiara Foroni; Daniele Generali; Giovanna Damia
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 4.  The role of PARP in DNA repair and its therapeutic exploitation.

Authors:  M Javle; N J Curtin
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

5.  Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair.

Authors:  Jaime Matta; Carmen Ortiz; Jarline Encarnación; Julie Dutil; Erick Suárez
Journal:  Int J Mol Sci       Date:  2017-07-12       Impact factor: 5.923

6.  High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.

Authors:  Hyelin Na; Jinil Han; Na-Lee Ka; Min-Ho Lee; Yoon-La Choi; Young Kee Shin; Mi-Ock Lee
Journal:  Breast Cancer Res       Date:  2019-11-28       Impact factor: 6.466

7.  Association of XPF Levels and Genetic Polymorphism with Susceptibility to Ischemic Stroke.

Authors:  Ying Ma; Xiao-Dong Deng; Yu Feng; Wei Zhang; Sun-Xian Wang; Yun Liu; Hong Liu
Journal:  J Mol Neurosci       Date:  2016-02-18       Impact factor: 3.444

8.  Calpain system protein expression in basal-like and triple-negative invasive breast cancer.

Authors:  S J Storr; K W Lee; C M Woolston; S Safuan; A R Green; R D Macmillan; A Benhasouna; T Parr; I O Ellis; S G Martin
Journal:  Ann Oncol       Date:  2012-06-27       Impact factor: 32.976

9.  Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.

Authors:  Li-Jun Di; Jung S Byun; Madeline M Wong; Clay Wakano; Tara Taylor; Sven Bilke; Songjoon Baek; Kent Hunter; Howard Yang; Maxwell Lee; Cecilia Zvosec; Galina Khramtsova; Fan Cheng; Charles M Perou; C Ryan Miller; Rachel Raab; Olufunmilayo I Olopade; Kevin Gardner
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.

Authors:  Tanguy Y Seiwert; XiaoZhe Wang; Jana Heitmann; Vivian Villegas-Bergazzi; Kam Sprott; Stephen Finn; Esther O'Regan; Allan D Farrow; Ralph R Weichselbaum; Mark W Lingen; Ezra E W Cohen; Kerstin Stenson; David T Weaver; Everett E Vokes
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.